Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
– Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April – – 89% CR,...
Alpha Tau Medical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Alpha Tau Medical to Participate in September Investor Conferences
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha
Alpha Tau Medical to Present at the Emerging Growth Conference on August 9th, 2023